Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegozafermin in Severe Hypertriglyceridemia
NCT05852431Phase 3Completed
- Sponsor
- 89bio
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Carrier/Scaffold Proteins
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of pegozafermin in hypertriglyceridemia (3 arms), sponsored by 89bio. Primary endpoint: Percent change from baseline in fasting triglycerides at 26 weeks. Started Jun 2023; status: completed.
02
Drugs
pegozafermin
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05852431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852431.